SUCCESSFUL CO-TREATMENT OF BCR-ABL LEUKEMIC CELLS WITH PONATINIB, AN ABL KINASE INHIBITOR, AND VORINOSTAT, A HISTONE DEACETYLASE INHIBITOR: A POTENTIAL TREATMENT FOR BCR-ABL POSITIVE LEUKEMIA CELLS

被引：0
|
作者：
Okabe, S. [1 ]
Tauchi, T. [1 ]
Kimura, S. [2 ]
Maekawa, T. [3 ]
Ohyashiki, K. [1 ]
机构：
[1] Tokyo Med Univ, Tokyo, Japan
[2] Saga Univ, Saga, Japan
[3] Kyoto Univ Hosp, Kyoto, Japan
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0521
引用
收藏
页码：210 / 210
页数：1
相关论文
共 50 条
  • [1] Combining ABL1 Kinase Inhibitor, Ponatinib and the Histone Deacetylase (HDAC) Inhibitor Vorinostat: A Potential Treatment for BCR-ABL Positive Leukemia Cells
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Kimura, Shinya
    Maekawa, Taira
    Ohyashiki, Kazuma
    BLOOD, 2011, 118 (21) : 612 - 612
  • [2] Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Kimura, Shinya
    Maekawa, Taira
    Kitahara, Toshihiko
    Tanaka, Yoko
    Ohyashiki, Kazuma
    PLOS ONE, 2014, 9 (02):
  • [3] The Efficacy of Histone Deacetylase Inhibitor, Vorinostat against BCR-ABL Positive Leukemia Cells Include ABL Kinase Domain Mutation in Monotherapy and in Combination with Dasatinib
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Kimura, Shinya
    Maekawa, Taira
    Ohyashiki, Kazuma
    Ashihara, Eishi
    BLOOD, 2008, 112 (11) : 1096 - 1096
  • [4] Selective killing of BCR-ABL positive cells with a specific inhibitor of the ABL tyrosine kinase
    Druker, BJ
    Ohno, S
    Buchdunger, E
    Tamura, S
    Zimmermann, J
    Lydon, NB
    CANCER GENES: FUNCTIONAL ASPECTS, 1996, 7 : 255 - 267
  • [5] Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
    Druker, BJ
    Tamura, S
    Buchdunger, E
    Ohno, S
    Segal, GM
    Fanning, S
    Zimmermann, J
    Lydon, NB
    NATURE MEDICINE, 1996, 2 (05) : 561 - 566
  • [6] Combining ABL1 Kinase Inhibitor, Imatinib and the Jak Kinase Inhibitor TG101348: A Potential Treatment for Residual BCR-ABL Positive Leukemia Cells
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Katagiri, Seiichiro
    Tanaka, Yuko
    Ohyashiki, Kazuma
    BLOOD, 2012, 120 (21)
  • [7] Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia
    Santos, Fabio P. S.
    Kantarjian, Hagop
    Cortes, Jorge
    Quintas-Cardama, Alfonso
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (12) : 1450 - 1465
  • [8] Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib
    Amin, Syed O.
    Ruzicka, Marcel
    Burns, Kevin D.
    Bence-Bruckler, Isabelle A.
    Ryan, Stephen E.
    Hadziomerovic, Adnan
    Hiremath, Swapnil
    JOURNAL OF CLINICAL HYPERTENSION, 2020, 22 (04): : 678 - 682
  • [9] Generation of BCR-ABL positive leukemic cell lines resistant to a selective ABL kinase inhibitor.
    leCoutre, P
    Marchesi, E
    Bertazzoli, C
    Pocliani, E
    GambacortiPasserini, C
    BLOOD, 1997, 90 (10) : 2211 - 2211
  • [10] Dasatinib -: Treatment of leukemia treatment of solid tumors Bcr-Abl and Src kinase inhibitor
    McIntyre, J. A.
    Castaner, J.
    Bayes, M.
    DRUGS OF THE FUTURE, 2006, 31 (04) : 291 - 303
12345